Combination of cadherin-17 and SATB homeobox 2 serves as potential optimal makers for the differential diagnosis of pulmonary enteric adenocarcinoma and metastatic colorectal adenocarcinoma.

Tingting Bian,Li Qian,Jianguo Zhang,Qing Zhang,Jian Liu,Jinli Zhao,Jia Feng,Daishan Jiang,Yifei Liu

doi:10.18632/oncotarget.18828

Abstract

BackgroundPulmonary enteric adenocarcinoma (PEAC), a rare type of non-small cell lung cancer, has similar histological and immunohistochemical morphology to colorectal adenocarcinoma. Cadherin-17 (CDH17) and SATB homeobox 2 (SATB2) immunoexpression have recently been demonstrated in colorectal adenocarcinoma. In this study, we evaluated the value of CDH17 and SATB2 in the diagnosis of pulmonary enteric adenocarcinoma and metastatic colorectal adenocarcinoma.MethodsA total of 13 PEAC cases and 27 metastatic colorectal adenocarcinoma cases were enrolled in our cohort study. We analyzed the expressions of CK7, CK20, CDX-2, villin, cadherin-17 (CDH17), and SATB homeobox 2 (SATB2) using immunohistochemistry. Staining intensity and percentage of positive-staining cells were recorded. Sensitivity and specificity values for immunostains, individually and in combination, were computed and compared.ResultsCombining CDH17 and SATB2 resulted in high sensitivity (76.92%) and specificity (100%). In our study, the use of CK7+, napsin A+, TTF-1+, napsin A+TTF-1+ in combination with CDH17-/SATB2- had a higher area under the curve compared to the combination CDH17-/SATB2-. However, no significant differences were observed between the combination CDH17-/SATB2- and other combinations (P>0.05).ConclusionsIn combination, CDH17 and SATB2 serve as potential optimal markers for the differential diagnosis of PEAC and metastatic colorectal adenocarcinoma.

Highlights

Since Tsao et al [1] first diagnosed primary pulmonary adenocarcinoma with enteric differentiation (PEAC), and increasing number of studies have reported on this condition
We evaluated the value of CDH17 and SATB homeobox 2 (SATB2) in the diagnosis of pulmonary enteric adenocarcinoma and metastatic colorectal adenocarcinoma
Based on the pathological data of the 13 patients with Pulmonary enteric adenocarcinoma (PEAC) (Table 1), we found the proportion of intestinal differentiation region to be 50%–85% and mitotic figures to occur at a rate of 2–9/10 HPF

Summary

Introduction

Since Tsao et al [1] first diagnosed primary pulmonary adenocarcinoma with enteric differentiation (PEAC), and increasing number of studies have reported on this condition. PEAC has histological and immunohistochemical similarities to colorectal adenocarcinoma, while some PEACs are positive for immunohistochemical markers of enteric differentiation, such as CDX-2 and CK20/7. Pulmonary enteric adenocarcinoma (PEAC), a rare type of nonsmall cell lung cancer, has similar histological and immunohistochemical morphology to colorectal adenocarcinoma. We evaluated the value of CDH17 and SATB2 in the diagnosis of pulmonary enteric adenocarcinoma and metastatic colorectal adenocarcinoma. We analyzed the expressions of CK7, CK20, CDX-2, villin, cadherin-17 (CDH17), and SATB homeobox 2 (SATB2) using immunohistochemistry. Conclusions: In combination, CDH17 and SATB2 serve as potential optimal markers for the differential diagnosis of PEAC and metastatic colorectal adenocarcinoma

Methods

Results

Conclusion